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Abstract
Interferon regulatory factor-1 (IRF-1) is a candidate
transcription factor for the regulation of the Toll-like
receptor-4 (TLR-4) gene. Using a small interfering RNA–
based (siRNA) process to silence IRF-1 gene expres-
sion in the leukemic monocytic cell line THP-1, we
investigated whether such a modulation would alter
TLR-4 expression and activation status in these cells.
The siIRF-1 cells expressed elevated levels of TLR-4
mRNA and protein compared to controls by 90% and
77%, respectively. ICAM.1 protein expression and apop-
tosis levels were increased by 8.35- and 4.25-fold, re-
spectively. The siIRF-1 cells overexpressed Bax mRNA
compared to controls. Proteomic analysis revealed up-
modulation of the Annexin-II protein in siIRF-1 THP-1
cells. Myelodysplastic syndrome (MDS) patients with an
absence of full-length IRF-1 mRNA also overexpressed
Annexin-II. It is plausible that this overexpression may
lead to the activation of TLR-4 contributing to the in-
creased apoptosis characterizing MDS.
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Introduction
The interferon regulatory factor (IRF) family comprises 10
structurally related transcription factors, each mediating
interferon (IFN) signaling and capable of regulating certain
cellular processes including cell proliferation, differentiation,
and cell death [1]. They all share homology in their amino
terminal region that encompasses the DNA binding domain
through which IRF family members recognize and bind to
similar DNA sequences in the promoter of a variety of genes
[2]. IRF-1 is a transcription factor involved in cell growth
control, induction of apoptosis, and cell transformation by
oncogenes [3–5]. The deletion of one or both alleles of the
IRF-1 gene has been observed in acute myeloid leukemia,
myelodysplasia, esophageal carcinomas, and gastric adeno-
carcinomas suggesting that this transcription factor acts as
a tumor suppressor gene [6–10]. IRF-1’s activities encom-
pass maturation of cells mediating immune responses and regu-
lation of the early events governing myeloid cells’ terminal
differentiation [11]. IRF-1 usually acts through the formation of
induction complexes with other transcription factors. More spe-
cifically, IRF-1, PU.1, and IFN consensus sequence binding pro-
tein (ICSBP ), another IRF family member solely expressed in
hematopoietic cells, compose a complex in the bone marrow
which recognizes and binds to IRF–PU.1 sites in the promoters
of several genes, one of which is the Toll-like receptor-4 (TLR-4 )
gene [12].
TLR-4 is a member of a conserved family of type I trans-
membrane receptors, which are characterized by an intracel-
lular signaling domain homolog to the interleukin-1 receptor.
These receptors recognize microbial components, particularly
bacterial lipopolysaccharide (LPS) [13,14]. Self molecules, in-
cluding danger signals (heat shock proteins) or products of
macromolecular degradation (fibronectin fragments), have
been shown to act as TLR-4 ligands [15,16]. On ligation, TLR
signaling triggers the expression of proinflammatory cytokines,
chemokines, costimulatory, and adhesion molecules (CD54/
ICAM.1), priming the adaptive immune system and initiating
the inflammatory responses [17–19].
Recently, the involvement of IRFs in innate and adaptive
immune responses has gathered substantial interest [20]. The
aim of this study was to evaluate the association between
the IRF-1 transcription factor and TLR-4 expression. We used
RNA interference to silence IRF-1 gene expression in the THP-
1 cell line to investigate whether this modulation would affect
TLR-4 expression and activation in these cells. Small interfer-
ing RNA–based (siRNA) strategy was preferred as knock-out
mice studies have found it too complex to define the effects of
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IRF-1 loss in bone marrow. Moreover, it has been proven that
RNA interference is a functional pathway of gene silencing,
having a biologic impact on myeloid leukemia cell lines [21].
Additionally, two-dimensional (2D) gel electrophoresis was
used for the identification of obliterated or newly expressed
proteins after IRF-1 loss.
Materials and Methods
Specific Reagents
PE-conjugated anti–TLR-4 (clone HTA125) was from
eBioscience (San Diego, CA). Immunoglobulin G (isotype
control) monoclonal antibody, fluorescein isothiocyanate–
conjugated Annexin-V and PE-conjugated anti-ICAM.1 were
obtained from Becton Dickinson (San Jose, CA). Lipopolysac-
charide (Escherichia coli, serotype O55:B5) was purchased
from Sigma (St. Louis, MO) and used at a concentration
of 1 mg/ml. Titration experiments were carried out to select
the optimal concentration of all the reagents. All values pre-
sented in the study are the mean value of three indepen-
dent experiments.
Small Interfering RNA–Based Process
The siRNA strategy [22] was employed to silence the en-
dogenous IRF-1 in THP-1 cells. IRF-1 and scrambled siRNA
were generated using Donze’s procedure and an in vitro tran-
scription system (T7 RiboMAX Express RNAi; Promega,
Madison, WI). Briefly, the siRNA sequences for IRF-1 and
primers were chosen using a web-based tool (siRNA Target
Designer; Promega). The primers are: IRF-1 si-SS sense 5V–
AAGTAATTTCCCTTCCTCATCTATAGTGAGTCGTATTAG-
GATCC–3V and IRF-1 si-AS antisense 5V–AAGATGAGGAA-
GGGAAATTACTATAGTGAGTCGTATTAGGATCC–3V. Target
sequences for IRF-1 gene are underlined, and the remaining
3V regions correspond to T7 promoter sequences. T7 si primer,
5V–GGATCCTAATACGACTCACTATAG–3V, was synthesized
and scrambled primers (sense and antisense) were also
created as siRNA control. The double-stranded 21-nucleotide
RNA were generated according to the manufacturer’s rec-
ommendations. The concentration of siRNA was optimized
at 1.8 mg in each transfection.
THP-1 Cell Cultures and Transfection
THP-1 cells were cultured in RPMI-1640 (Gibco, Carls-
bad, CA) supplemented with 10% FBS, 5  105 M 2-
mercaptoethanol, 2 mM L-glutamine, 100 U/ml penicillin,
and 100 mg/ml streptomycin. Cells were regularly passaged
to maintain exponential growth. Twenty-four hours before
transfection, cells were diluted in fresh medium without anti-
biotics and transferred to 24-well plates. Transient transfec-
tion of siRNA was performed using a reagent (GeneEraser;
Stratagene, La Jolla, CA) according to the manufacturer’s
recommendations. The efficiency of the transfection was
monitored every 12 hours. At 36 hours, IRF-1 expression
was totally inhibited. Taking this into account and given that
IRF-1 protein has a half-life of 0.5 hours, we estimated the
decreased rate to be (1/2)2 with  representing each hour
after IRF-1 transcriptional inactivation (Figure 1B ). Using
this model, we set harvesting time at 60 hours posttransfec-
tion. Specific silencing was confirmed by at least three in-
dependent experiments. The cells were also treated with
transfection reagent alone or with the nonsilencing scram-
bled siRNA (scrIRF-1 siRNA) to be used as controls.
Two-Dimensional Gel Electrophoresis
Protein was extracted from 2  106 THP-1 cells using a
lysis buffer (0.5% w/v CHAPS, 8 M urea, 0.2% w/v DTT, and
0.5% v/v immobilized pH gradient buffer pH 3–10). Immobi-
lized pH gradient strips [18 cm, pH 3–10] were rehydrated
for 20 hours with the sample solution (total protein amount of
150 mg assessed by Bradford analysis). Proteins were fo-
cused using a platform (Ettan IPGphor, San Francisco, CA)
for 1 hour at 1000 V and for 4 hours at 8000 V. Strips were
then equilibrated (50 mM Tris–HCl pH 6.8, 6 M urea, 30%
glycerol, 2% SDS, and 1% DTT) and run overnight onto SDS-
PAGE (acrylamide/bisacrylamide ratio of 4:0.232) at 90 V.
Finally, the protein zones were identified with silver staining.
Protein Identification By Mass Spectrometry
The spots of interest were excised from gels and digested
overnight with sequence grade trypsin (Promega). The elu-
ate was analyzed on an ion trap mass spectrometer with a
nanospray source (LCQ Deca; ThermoFinnigan, Baltimore,
MD). The interpretation of both the mass spectrometry (MS)
and tandem mass spectrometry (MS/MS) data was carried
out by search in protein databases (SwissProt) using the
Turbo-SEQUEST search engine.
mRNA Analysis
Total RNA was collected as previously described [23].
Real-time polymerase chain reaction (PCR) was used to
confirm the integrity and perform the normalization of all
cDNA samples through the amplification of the 18S ribo-
somal RNA (rRNA), which served as the housekeeping
gene. The primers’ sequences used are described in Table 1.
Quantitative Real-Time PCR
mRNA levels were quantified by real-time PCR. We de-
signed oligonucleotide primers for each mRNA, in accor-
dance with the published sequences (Table 1). All values
were measured as the number of amplicons normalized
against 18S rRNA, a housekeeping gene, as previously de-
scribed [23,24].
Flow Cytometry
The expression of various proteins was investigated by
flow cytometry analysis, either constitutively or following ap-
propriate stimulation, as previously described [24].
Immunohistochemistry
We investigated the expression of Annexin-II protein by
immunohistochemistry, using a monoclonal antibody specific
to the Annexin-II (Becton Dickinson). We used paraffin-
embedded bone marrow biopsy tissues from 10 myelodys-
plastic syndrome (MDS) patients characterized by absence
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(n = 5) or presence (n = 5) of full-length IRF-1 mRNA, three
acute promyelocytic leukemia patients with documented
Annexin-II overexpression (positive controls) and three nor-
mal individuals (negative controls) [23,25]. Annexin-II expres-
sion was measured as the percentage of immunoreactive
cells per 1000 nucleated cells in 10 fields per preparation.
Statistical Analysis
Mann-Whitney U tests were used for data comparison.
Results
siIRF-1 THP-1 Cell Cultures
The IRF-1mRNA expression was inhibited 36 hours post-
transfection, as assessed by PCR or real-time PCR (Fig-
ure 1A) in the cells treated with the silencing siRNA (siIRF-1
THP-1 cells). The cells treated with transfection reagent alone
and those transfected with no silencing scrambled siRNA
(scrIRF-1 THP-1 cells) showed no change in IRF-1mRNA ex-
pression, supporting the efficiency of the siRNA strategy. The
expression of -actin (PCR) and 18S rRNA (real-time PCR)
among the three groups remained unchanged (data not
Figure 1. Small interfering RNA for the transcriptional inhibition of IRF-1. (A) The IRF-1 transcriptional expression as assessed by real-time PCR. At 36 hours
posttransfection, no IRF-1 mRNA was detected. IRF-1 expression was restored 136 hours posttransfection. The transcriptional expression of -actin (PCR) and 18S
rRNA (real-time PCR) were not disturbed by the process. The THP-1 cells treated with transfection reagent alone or non-silencing scrambled siRNA revealed no
change in IRF-1 expression. (B) A mathematical approach of the degradation rate of the constitutive IRF-1 protein levels posttransfection. At 36 hours after the
addition of the siRNA, the transcription of IRF-1 was inhibited. The already formed IRF-1 protein levels (constitutive) would drop by 50% every 30 minutes (half-life).
We estimated that, at 42 hours posttransfection, the IRF-1 protein levels would be less than 0.1% of the constitutive. To further minimize the margin of error, we set the
LPS induction at 52 hours and the harvesting time at 60 hours posttransfection. (C) Schematic representation of the IRF-1 protein’s functional domains and the mRNA.
The known functional domains of the IRF-1 protein are depicted and correlated with the genomic arrangement of the full-length transcript. The black boxes represent
the translated areas. The asterisk indicates the complementary site of the siRNA, which is outside the conserved region shared by the IRF family members.







18S rRNA NG_002801 1151–1453 302 1.98
IRF-1 NM_002198 391–605 214 1.83
TLR-4 NM_003266 3035–3370 355 1.91
Bax NM_138761 1804–2053 249 1.86
Bcl-2 NM_000633 1078–1313 236 1.88
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shown), confirming the high specificity of the siRNA strategy
(Figure 1).
TLR-4 Is Upregulated in THP-1 siIRF-1 Cells
TLR-4 expression was examined by quantitative real-time
PCR and FACS analysis. We observed significantly higher
levels of TLR-4 in siIRF-1 THP-1 cells in comparison with the
scrIRF-1 THP-1 cells. The siIRF-1 THP-1 cells presented a
90 ± 10% and 77 ± 8% increase in the TLR-4 mRNA and
protein levels, respectively (P < .01) (Figure 2, A and B). To
investigate the potential implication of IRF-1 in the LPS-
driven TLR-4 levels, LPS was added at 52 hours posttrans-
fection (8 hours of induction) in all cell groups. The scrIRF-1
THP-1 cells treated with LPS showed 25 ± 3% increase
in TLR-4 protein levels in comparison with the untreated
scrIRF-1 THP-1 cells. The LPS-stimulated siIRF-1 THP-1
cells showed no change in the TLR-4 protein levels com-
pared to the untreated siIRF-1 THP-1 cells. Overall, the LPS-
treated siIRF-1 THP-1 cells presented a 46 ± 8% increase
in TLR-4 protein levels in contrast to the LPS-triggered
scrIRF-1 THP-1 cells (Figure 2B). These results suggest
that IRF-1 is implicated in the expression of TLR-4 because
its silencing fully activated TLR-4 on siIRF-1 THP-1 cells to
the extent that their levels remained unchanged despite mild
LPS treatment.
ICAM.1 (CD54) Is Upregulated in THP-1 siIRF-1 Cells
The adhesion molecule ICAM.1 is a surrogate marker for
TLR-mediated activation. The siIRF-1 THP-1 cells presented
an 8.35-fold increase (P < .01) in their ICAM.1 protein levels,
in contrast to the scrIRF-1 THP-1 cells (Figure 2C). Follow-
ing LPS stimulation, the scrIRF-1 THP-1 cells presented a
31.7-fold increase in ICAM.1 protein levels in comparison
with the untreated cells (P < .01). The siIRF-1 THP-1 cells
challenged with LPS, revealed a 27.3-fold increase in ICAM.1
levels when compared to the untreated siIRF-1 THP-1 cells
(P < .01). Overall, the LPS-stimulated siIRF-1 THP-1 cells
presented a 3.98-fold increase in ICAM.1 levels in contrast
to the LPS-stimulated scrIRF-1 THP-1 cells (P < .01) (Fig-
ure 2C). The increase of ICAM.1 expression in the siIRF-1
THP-1 cells advocates that IRF-1 inhibition is suffice to ac-
tivate TLRs.
Figure 2. siIRF-1 THP-1 cells present elevated levels of TLR-4 and ICAM.1
protein levels as well as increased Annexin-V+ staining. (A) The siIRF-1 THP-
1 cells presented a 90 ± 10% increase of the TLR-4 mRNA levels when
compared to the scrIRF-1 THP-1 cells (P < .01). (B) The siIRF-1 THP-1 cells
presented a 77 ± 8% increase of the TLR-4 protein levels when compared to
the scrIRF-1 THP-1 cells (P < .01). The scrIRF-1 THP-1 cells treated with
LPS presented elevated TLR-4 protein levels by 25 ± 3% in comparison with
the untreated cells. The siIRF-1 THP-1 cells challenged with LPS showed
no differences in the TLR-4 protein levels when compared to the untreated
siIRF-1 THP-1 cells. Finally, the LPS-treated siIRF-1 THP-1 cells presented a
46 ± 8% increase in the TLR-4 protein levels in contrast to the LPS-triggered
scrIRF-1 THP-1 cells. (C) The siIRF-1 THP-1 cells presented an 8.35-fold in-
crease in their ICAM.1 protein levels, in contrast to the scrIRF-1 THP-1 cells
(P < .01). The scrIRF-1 THP-1 cells treated with LPS presented a 31.7-fold
increase in ICAM.1 protein levels in comparison with the untreated cells (P <
.01). The siIRF-1 THP-1 cells challenged with LPS revealed a 27.3-fold
increase in ICAM.1 levels when compared to the untreated siIRF-1 THP-1
cells (P < .01). Finally, the LPS-treated siIRF-1 THP-1 cells presented a 3.98-
fold increase in ICAM.1 levels in contrast to the LPS-triggered scrIRF-1 THP-
1 cells (P < .01). (D) The constitutive levels of apoptosis (Annexin-V +) in the
scrIRF-1 THP-1 cells were calculated at 7 ± 2% of the total population. The
siIRF-1 THP-1 cells presented a significant increase in apoptosis (4.25-fold)
with the Annexin-V+ positive cells reaching 29 ± 3% of the total population,
indicating that IRF-1 interference resulted in a 23% increase in cellular apop-
totic levels (P < .01). The scrIRF-1 THP-1 cells treated with LPS presented a
0.55-fold increase in Annexin-V+ staining (10.85 ± 2%) in comparison with the
untreated cells. The siIRF-1 THP-1 cells challenged with LPS (39.5 ± 4%),
revealed a 1.4-fold increase in the apoptotic levels when compared to the
untreated siIRF-1 THP-1 cells (P < .05). Finally, the LPS-treated siIRF-1
THP-1 cells presented a 3.6-fold increase in Annexin-V+ staining in contrast
to the LPS-triggered scrIRF-1 THP-1 cells (P < .01).
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Annexin-V+ Staining and Proapoptotic Bax mRNA
Are Upregulated in THP-1 siIRF-1 Cells
Annexin-V positive staining was employed to estimate
early and intermediate apoptosis. The constitutive levels of
apoptosis (Annexin-V+) in the scrIRF-1 THP-1 cells were cal-
culated at 7 ± 2% of the total population. The siIRF-1 THP-1
cells presented a significant increase in apoptosis (4.25-fold)
(P < .01) with the Annexin-V+ positive cells reaching 29 ± 3%
of the total population indicating that IRF-1 interference re-
sulted in a 23% increase in cellular apoptotic levels (P < .01)
(Figure 2D). To further investigate apoptosis in the scrIRF-1
THP-1 cells and siIRF-1 THP-1 cells, we examined the mRNA
expression levels of Bax (proapoptotic) and Bcl-2 (antiapop-
totic). The expression levels of Bax were elevated 1.6 times in
the siIRF-1 THP-1 cells when compared to the scrIRF-1 THP-1
cells (P < .05). The expression levels of Bcl-2 did not present
any differences between the two groups (Figure 3).
The scrIRF-1 THP-1 cells treated with LPS presented
a 0.55-fold increase in Annexin-V+ staining (10.85 ± 2%) in
comparison with the untreated cells. The siIRF-1 THP-1 cells
challenged with LPS (39.5 ± 4%) revealed a 1.4-fold increase
in the apoptotic levels when compared to the untreated siIRF-1
THP-1 cells (P < .05). Overall, the LPS-treated siIRF-1 THP-1
cells presented a 3.6-fold increase in Annexin-V+ staining in
contrast to the LPS-triggered scrIRF-1 THP-1 cells (P < .01)
(Figure 2D).
Identification of Differentially Expressed Proteins After
siRNA Treatment By 2D Gel Electrophoresis
IRF-1 inhibition caused alterations in the protein expres-
sion of THP-1 cells, in regard to 21 peptides (Figure 4). More
specifically, Annexin-II, tryptophanyl-tRNAsynthetase, ubiquitin-
activating enzyme E1, esterase D, and keratine type II cyto-
skeletal 1 were detected in the siIRF-1 THP-1 cells but not in
the scrIRF-1 THP-1 cells. The protein coverage of Annexin-II,
as calculated by MS, was 64.2% by amino acid count and
63.2% by mass.
Annexin-II Expression in MDS Bone Marrows
In silico analysis of the proteins that were differentially
expressed after siRNA treatment identified Annexin-II as the
most prominent protein to be involved in certain hematolog-
ical disorders, such as MDS. We have previously reported
that IRF-1 mRNA is either diminished or inactivated through
alternative splicing in human myelodysplasia [23]. We have
further reported that TLR-4 is upregulated in hemopoietic pro-
genitor cells of MDS patients, contributing to the increased
apoptosis of their bone marrow progenitor cells [24]. In this
study, LPS stimulation upregulated TLR-4 expression and
increased ICAM.1 expression in MDS marrow and in THP-1
cells that were used as controls [24]. Moreover, TLR-4 upre-
gulation was found to be tumor necrosis factor–mediated both
in MDS and in THP-1 cells, whereas apoptosis was similarly
Figure 3. mRNA expression of Bax and Bcl-2. (A) The mRNA expression of Bax, Bcl-2, and -actin in scrIRF-1 THP-1 cells and siIRF-1 THP-1 cells. (B) The
mRNA expression of Bax, Bcl-2, and -actin in scrIRF-1 THP-1 cells and siIRF-1 THP-1 cells, as it was studied with quantitative real-time PCR. The siIRF-1 THP-1
cells presented a 1.6-fold increase in the Bax mRNA levels when compared to the scrIRF-1 THP-1 cells (P < .05). The Bcl-2 mRNA expression presented no
statistically significant difference between the two groups.
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increased after tumor necrosis factor and LPS treatment [24].
In the present study, the expression of Annexin-II following
the siIRF-1 treatment of THP-1 cells prompted us to further
investigate Annexin-II expression in the bone marrow of MDS
patients with or without full-length IRF-1 mRNA, as well as in
the bone marrow of three patients with acute promyelocytic
leukemia, the latter being used as positive controls. The MDS
patients without full-length IRF-1 transcript presented a higher
Annexin-II expression than the MDS patients with IRF-1 full-
length transcript. A gradual increase in the immunoreactive
index was observed among normal controls (0.04 ± 0.02),
MDS patients displaying IRF-1 full-length transcript (0.40 ±
0.16), and MDS patients with an absence of the IRF-1 full-
length transcript (0.78 ± 0.11) (P < .05). The highest score was
noted in the acute promyelocytic leukemia group of patients
(0.96 ± 0.39) (Figure 5).
Discussion
IRF-1 plays a central role in immune and inflammatory re-
sponses. Being a key transcriptional activator of the IFNa/
genes in virus-infected cells, it orchestrates fundamental pro-
cesses of innate immunity [26]. Recent studies have dem-
onstrated that IRFs are also involved in the regulation of TLR
expression [20,27]. With this report, we demonstrate that
IRF-1 silencing through RNA interference, leads to an over-
expression of TLR-4 in THP-1 cells. THP-1 cells activate
NF-nB and other transcription factors in response to TLR li-
gands and cytokines. Unlike other cell lines, which are en-
gineered to respond to TLR agonists, THP-1 cells naturally
express the TLR genes and others involved in TLR-signal
cascade, thereby constituting a useful and convenient model
system for TLR studies [28]. Consequently, the use of THP-1
cells to investigate the association of IRF-1 and TLR-4 is apt.
A composite binding site for both the IRF family members
and PU.1, an Ets transcription factor, has been located in the
promoter of TLR-4 adjacent to the inner purine-rich motif
[12]. A similar site has been identified and examined in the
promoter of the CYBB gene that encodes for gp91phox, a
subunit of the phagocyte respiratory burst oxidase catalytic
unit [29]. It has been demonstrated that PU.1 is essential
for the formation of the multiprotein transcription complexes
in which IRF-1 and ICSBP can participate either solely or
together. ICSBP binds to its target DNA sequence following
association with either IRF-1 or IRF-2, through a conserved
domain known as the IRF-1 association domain [30]. While
being structurally similar and recognizing the same DNA
Figure 4. Identification of differentially expressed proteins after IRF-1 interference. (A) Two-dimensional electrophoresis was employed to investigate any
differentiated protein expression profile before (right gel) and after (left gel) IRF-1 transcriptional interference. The mass spectrometry that followed identified the
appearance of five protein spots solely in the siIRF-1 gel, namely Annexin II, tryptophanyl-tRNA synthetase, ubiquitin-activating enzyme E1, esterase D, and
keratine type II cytoskeletal 1. (B) Two of the peptides as analyzed by MS/MS. (C) The Annexin-II protein sequence. The positions of the peptides that were
identified by MS are underlined.
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sequences, the IRF-1 and IRF-2 are functionally distinct,
being competitive inhibitors of each other at the transcrip-
tional level [31]. Furthermore, the 8-hour half-life of IRF-2
engenders long-lasting transcription complexes, in contrast
to IRF-1 characterized by 30 minutes of half-life. The precise
mechanism, by which IRF-1 interferes with TLR-4 inducion,
remains elusive. TLR-4 overexpression in siIRF-1 THP-1 cells
could be attributed to the formation of an altered transcription
complex, comprising either PU.1 and ICSBP alone or the sub-
stitution of IRF-1 by the more stable IRF-2.
Although IRF-1 has been directly implicated in the regu-
lation of the TLR-4 gene, as yet no direct relationship be-
tween IRF-1 and TLR-4 activation has been reported. In our
study, we show that TLR-4 not only presented elevated
levels in siIRF-1 THP-1 cells compared to the control group,
but it was also characterized by activation, with ICAM.1 being
significantly upregulated in IRF-1 silenced cells. Proteomic
analysis revealed an up-modulation of Annexin-II protein in
siIRF-1 THP-1 cells. Annexin-II, a phospholipid-binding pro-
tein, serves as a platform on the cell surface for the binding of
both plasminogen and tissue plasminogen activator [32]. By
anchoring both these molecules in close proximity to each
other, Annexin-II provides an environment that enhances
plasmin production by protecting the fibrinolytic enzymes from
their inhibitors. Furthermore, the elevated expression of
Annexin-II in leukemic cells correlates with their in vitro ability
to generate plasmin. This results in increased fibrinolysis,
production of fibronectin fragments, and plasmin-mediated
proteolytic activation of metalloproteinases [24,33]. The up-
modulation of Annexin-II in IRF-1 silenced cells could lead to
an elevated plasmin activity that gives rise to an abundance of
fibronectin fragments. Such fragments are well-known TLR-4
ligands and could account for their activation.
LPS binding to TLR-4, triggers activation of the cellular
signaling pathways resulting in nuclear translocation of
NF-nB and apoptosis [34]. The molecular mechanism that
links the upstream NF-nB signaling to the recruitment and
activation of caspases remains unclear. TLR triggering has
been linked to excessive programmed cell death through
the Fas-associated death domain pathway [35–37]. TLR-4
and its respective intracellular binding partners, MyD88,
Mal/TIRAP, along with the extrinsic Fas-associated death
domain–caspase 8 pathway, have been shown to mediate
LPS-induced apoptosis. However, questions remain as to
how this signaling pathway activates the effector proteases
of apoptosis [38,39]. It has been suggested that members of
Figure 5. Expression of Annexin II on bone marrow biopsies by immunohistochemistry. Panels A, B, and C are derived from a control, an MDS patient without
IRF-1 full-length, and an acute promyelocytic leukemia, respectively (magnification, 20), whereas panels D and E are derived from MDS patients with and without
IRF-1, respectively, under higher magnification (40). (A) Normal donor characterized by the presence of the IRF-1 full-length transcript. The expression of
Annexin-II is limited only to the cytoplasm of the myeloid cells. The immunoreactivity in this group (n = 3) is estimated at 0.04 ± 0.02. (B) MDS patient characterized
by the absence of the IRF-1 full-length transcript. Annexin-II positive staining was detected in all myeloid cells and partially in the erythroid cells. The
immunoreactivity in the MDS patients characterized by the absence of the IRF-1 full-length transcript (n = 5) was evaluated at 0.78 ± 0.11. (C) Representative of an
acute promyelocytic leukemia patient. In this group (n = 3), the Annexin-II staining was universal and the immunoreactivity percentage reached 0.96 ± 0.039.
Interestingly, this type of leukemia is characterized by the absence of the IRF-1 full-length transcript. (D) MDS patient characterized by the absence of IRF-1 full-
length transcript. The Annexin-II (as assessed by staining) is concentrated in the membrane of the cell. (E) MDS patient characterized by the presence of IRF-1 full-
length transcript. The Annexin-II (as assessed by staining) is localized in both the membrane and the cytoplasm. In the MDS patients characterized by the presence
of the IRF-1 full-length transcript (n = 5), the immunoreactivity is estimated at 0.40 ± 0.16.
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the Bcl-2 family play the role of mediator in LPS-induced
apoptosis. LPS upregulates the expression of the proapop-
totic Bcl-2 family members Bax, Bad, and Bak, and down-
regulates the levels of the antiapoptotic members, such as
Bcl-2 and Bcl-xL [40,41]. In addition, the vascular endothelial
growth factor that inhibits LPS-induced upregulation of the
proapoptotic Bcl-2members provides protection against LPS-
induced endothelial cell apoptosis [42]. Our results further
support these data, showing that overexpression and acti-
vation of TLR-4 in IRF-1 silenced cells are accompanied
by increased apoptosis. Although the mechanism by which
TLR-4–elicited apoptosis remains unknown, our data im-
plicate a role for Bcl-2 family proteins in determining THP-1
apoptosis after TLR-4 activation.
We have previously reported that the bone marrow he-
matopoietic cells of MDS patients either abolish their IRF-1
expression or present spliced variants with functional dereg-
ulation [23,43]. We further reported that TLR-4 is not only
significantly upregulated in CD34+ cells in MDS patients but
is also involved in promoting apoptosis, possibly contributing
to MDS cytopenia [24]. In the latter study, the response of the
THP-1-stimulated cell line used as control was similar to that
of bone marrow cells derived from MDS patients following
identical stimulation with the TLR-4 ligand LPS. This prompted
us to investigate the presence of Annexin-II in bone marrow
biopsies of MDS patients with or without full-length IRF-1
mRNA expression. Indeed, immunohistochemistry revealed
the abundant presence of Annexin-II in MDS patients with
absence of full-length IRF-1mRNA. This is in accordance with
the overexpression of Annexin-II in siIRF-1 THP-1 cells.
Whether this abundance of Annexin-II in the MDS bone
marrow environment is pathogenetically implicated in the
TLR-4 overexpression and activation in these patients war-
rants further investigation.
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